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mortality in women 1. Approximately 6% of women 
with breast cancer are metastatic at diagnosis 2, a rate 
that will account for just over 1300 new breast cancer 
diagnoses in Canadian women in 2007 1,2.
Unfortunately, many women with early breast 
cancer will be diagnosed with a metastatic relapse in 
the years following treatment with locoregional and 
systemic adjuvant therapies. The goals of treatment 
in metastatic breast cancer include prolongation of 
survival, symptom control, and maintenance of quality 
of life. In Alberta, chemotherapy for breast cancer is 
prescribed at tertiary, associate, and community can-
cer clinics, all of which are affiliated with the Alberta 
Cancer Board.
The literature on taxanes and breast cancer has 
been growing exponentially since the mid-1990s. In 
the absence of an evidence-based provincial guide-
line, regional variability in taxane prescription is to 
be expected. The objective of creating a provincial 
guideline on the optimal use of taxanes in the man-
agement of metastatic breast cancer is to promote 
evidence-based consistency in practice and hence 
equitable patient access to appropriate therapies. 
Guidelines for taxane use in the management of meta-
static breast cancer have previously been published. 
The guidelines published here were developed by 
the Alberta Cancer Board Provincial Breast Tumour 
Group Guideline Panel by systematically adapting the 
recommendations of others and by creating de novo 
recommendations to account for recent evidence.
2.  APPROACH TO GUIDELINE DEVELOPMENT
2.1  Objective
The objective was to determine the optimal clinical use of 
taxanes in the management of metastatic breast cancer.
2.2  Key Clinical Questions
Which taxane regimens can be offered to an- • 
thracycline-naïve patients with metastatic breast 
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The role of taxanes in the treatment of breast cancer 
is becoming increasingly important. In clinical prac-
tice, the taxanes are now standard therapy in both 
early-stage and metastatic breast cancer. Since the 
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evaluating the efficacy of taxanes in the treatment of 
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other chemotherapeutic agents. Pre-existing published 
guidelines for the use of taxanes in the management of 
metastatic breast cancer are available. The mandate of 
the Alberta Cancer Board Provincial Breast Tumour 
Group Guideline Panel was to consider and adapt 
the recommendations of the existing guidelines and 
to develop de novo guidelines to account for current 
evidence. For this task, the panel used the a d a p t e  
process, which is a systematic process of guideline 
adaptation developed by the a d a p t e  Collaboration.
The recommendations formulated by the panel in-
cluded the identification of taxane regimens that could 
be offered in anthracycline-naïve patients, anthracy-
cline-pretreated or -resistant patients, and patients 
overexpressing the human epidermal growth factor 
receptor 2. Potential toxicities and benefits in terms of 
time to progression, progression-free survival, overall 
survival, and quality of life were also considered.
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1.  INTRODUCTION
For 2007, breast cancer is projected to be the second 
most commonly diagnosed cancer, and the third lead-
ing cause of cancer-related mortality in Canadian 
women 1. Cancer was the leading cause of potential 
life–years lost in Canadian adults in 2003, and breast 
cancer accounted for 18.3% of cancer-related premature PRACTICE GUIDELINE SERIES
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cancer [in which the human epidermal growth 
factor receptor 2 (h e r 2) is not overexpressed]?
Which taxane regimens can be offered to an- • 
thracycline-pretreated or -resistant patients with 
metastatic breast cancer (in which h e r 2 is not 
overexpressed)?
Which taxane regimens can be offered to patients  • 
with metastatic breast cancer in which h e r 2 is 
overexpressed?
What are the benefits [time to progression ( •  t t p), 
progression-free survival (p f s), overall survival 
(o s ), quality of life (q o l )]?
What are the potential toxicities? • 
2.3  Target Population
The target population for the guideline is individuals 
with metastatic breast cancer (anthracycline-naïve 
or -pretreated or -resistant) who are eligible for pal-
liative chemotherapy (hormone refractory or rapidly 
progressive disease, with adequate performance status 
and organ function).
2.4  Target Users
The target users for the guideline are chemotherapy-
prescribing physicians, nurse practitioners, and 
pharmacists within the Alberta Cancer Board; the 
Alberta Cancer Board Pharmacy and Therapeutics 
Committee; and patients.
3.  METHODS
The guideline presented here was developed by the 
Alberta Cancer Board Provincial Breast Tumour 
Group Guideline Panel using the a d a p t e  process 3 
and some aspects of the practice guidelines develop-
ment cycle 4. Panel members included 4 medical on-
cologists, 1 oncology pharmacist, 1 oncology nurse, 
and 1 methodologist. All panel members disclosed 
information on potential conflicts of interest before 
the development process started (no conflicts were 
reported). The Alberta Cancer Board Provincial 
Breast Tumour Group Guideline Panel is editorially 
independent of the Alberta Cancer Board.
3.1  Literature Search Strategy
A systematic search of m e d l i n e , PubMed, c i n a h l , 
e m b a s e , CancerLit, the Cochrane Library, the Physi-
cian Data Query database, practice guideline internet 
sites, and conference proceedings from the American 
Society of Clinical Oncology (a s c o) and the San 
Antonio Breast Cancer Symposium was conducted 
for relevant, existing practice guidelines and other 
evidence. The search terms used were Taxane* Exp., 
Taxanes Exp., metastatic breast cancer exp., metas-
tases, breast tumor, Women exp., adding AND/OR 
Anthracycline exp., Anthracyclines exp.
The search for practice guidelines was conducted 
for the period January 1, 2000, to August 31, 2007. 
Given that the most up-to-date evidence-based prac-
tice guideline selected for the adaptation process was 
published in 2003, the search for other evidence was 
conducted for the period January 1, 2003, to Janu-
ary 1, 2007. Other evidence cited in bibliographies 
and brought forward during editing and review was 
collected as necessary.
3.2  Inclusion and Exclusion Criteria
Titles and abstracts (where possible) were assessed 
independently by 2 reviewers for relevance. A full copy 
of the publication or abstract (if only a conference 
proceeding) was obtained if either reviewer considered 
the item to be relevant. These documents were assessed 
for inclusion and exclusion criteria as follows:
For practice guidelines: • 
Pertaining to individuals with metastatic (not  1. 
locally advanced) breast cancer, anthracy-
cline-naïve or pretreated
Pertaining to palliative chemotherapy with  2. 
reference to taxanes or taxane-containing 
regimens (“taxanes” are docetaxel, paclitaxel, 
or nab-paclitaxel)
Published in the English language 3. 
Clear linkage between the recommendations  4. 
and the supporting literature
Presentation of a comprehensive review of  5. 
the relevant existing evidence with or without 
meta-analyses of data where appropriate
For other evidence: • 
Systematic review, randomized phase  1.  iii 
clinical trial, or randomized phase ii clinical 
trial reporting data on time to progression, 
p f s, o s , or q o l  (with or without data on re-
sponse rates)
Pertaining to individuals with metastatic (not  2. 
locally advanced) breast cancer, anthracy-
cline-naïve or pretreated
Pertaining to palliative chemotherapy in  3. 
which a taxane or taxane-containing regimen 
is compared with a non-taxane chemotherapy 
regimen or a different taxane chemotherapy 
regimen (“taxanes” are docetaxel, paclitaxel, 
or nab-paclitaxel)
Published in the English language 4. 
3.3  Data Synthesis
The Comprehensive Meta-analysis Package, version 2, 
was used for data pooling where deemed appropriate. 
Random effects models were used to obtain odds ratios 
or rate ratios.KING et al.
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3.4  External Review
A draft report was distributed for review to other 
members of the Alberta Cancer Board Provincial 
Breast Tumour Group with representation from medi-
cal oncology, nursing, and pharmacy. Reviewers were 
asked to read the guideline, complete a questionnaire 
(based on the questionnaire published in Elit et al. 5), 
and to provide other written comments.
4.  RESULTS
4.1  Literature Search
Two guidelines met the inclusion criteria and were 
considered relevant:
Cancer Care Ontario ( •  c c o )   The Role of the Taxanes in 
the Management of Metastatic Breast Cancer, Practice 
Guideline Report 1-3, version 2.2003 6
National Institute of Clinical Excellence ( •  n i c e )   Guid-
ance on the Use of Taxanes for the Treatment of Breast 
Cancer, Technology Appraisal Guidance no. 30, 
September 2001 7
Four guidelines did not fully meet guideline in-
clusion criterion 4:
Scottish  Intercollegiate  Guidelines  Network  • 
(s i g n)   Management of Breast Cancer in Women. A 
National Clinical Guideline, December 2005 8
British Columbia Cancer Agency ( •  b c c a)   Cancer 
Management Guidelines: A Guide for Women with 
Advanced Breast Cancer, August 2006 9
National Comprehensive Cancer Network ( •  n c c n )   In-
vasive Breast Cancer (“preferred chemotherapy 
regimens for recurrent or metastatic breast 
cancer”), Practice Guidelines in Oncology, 
v.2.2006 10
Central European Cooperative Oncology Group  • 
(c e c o g)   “Second consensus on medical treatment 
of metastatic breast cancer,” July 2006 11
The s i g n  guideline was discarded because the 
overall recommendation that “taxanes should be con-
sidered in patients with advanced disease” was felt 
to be too general. The b c c a , n c c n , and c e c o g  docu-
ments were not accompanied by a comprehensive 
literature review. Although the b c c a , n c c n , and c e c o g  
guidelines were not subjected to the formal a d a p t e  
process, the recommendations were deliberated 
because the group felt that they could be influencing 
current local practice.
With respect to other evidence, two systematic 
reviews and twenty-three randomized phase ii or 
iii trials initially met the inclusion criteria and were 
considered relevant. Sixteen publications from the 
literature search did not meet inclusion criteria or 
were not considered relevant. Eight other documents 
(related guidelines or trials) were obtained during 
editing and review.
4.2  External Review
Five completed questionnaires were returned. Table i 
shows the results for the 16 closed-ended questions. 
Responses were favourable (“agree” or “strongly 
agree” on a 5-point Likert scale). Only 1 reviewer 
marked “neutral” to one question: “When applied, 
the recommendations would result in better use of re-
sources than current usual practice.” One open-ended 
comment resulted in a change to the draft report. The 
reviewer suggested providing further explanation for 
the inclusion or exclusion of guidelines.
5.  DISCUSSION
The panel considered some general principles when 
adapting and creating de novo recommendations. 
First, for the question of benefit, emphasis was 
placed on gains in o s . Quality-of-life data usually 
did not differentiate regimens or were lacking. Op-
tions were not discarded based on toxicity data. 
Such data were described to allow for patient and 
physician preference. Second, because the optimal 
dose of some taxanes in some schedules has not yet 
been established, dose ranges reflecting those that 
have been studied in the various trials are presented. 
Deliberation of cost-effectiveness was beyond the 
scope of the present project.
5.1  Anthracycline-Naïve Patients
5.1.1  Recommendation 1
If single-agent chemotherapy is preferred, an anthra-
cycline followed sequentially by a taxane at the time 
of disease progression—or vice versa—is acceptable. 
A survival benefit has not been shown for starting 
with a taxane.
The following regimen is recommended:
Docetaxel 100 mg/m •  2 every 3 weeks
Weekly taxane regimens are also a reasonable 
option if minimization of risk for certain toxicities 
associated with every-three-weeks docetaxel is desired:
Docetaxel 35–40 mg/m •  2 weekly for 3 of every 
4 weeks, or weekly for 6 of every 8 weeks
Paclitaxel 80–90 mg/m •  2 weekly
Recommendations from Existing Guidelines:   The c c o  
guideline recommends that patients who would be 
offered treatment with a single-agent anthracycline 
could also be offered single-agent docetaxel 100 mg/
m2 every 3 weeks 6. The n i c e guideline does not pro-
vide guidance with respect to single-agent taxanes 
in anthracycline-naïve patients 7.PRACTICE GUIDELINE SERIES
11
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 3
The b c c a  and c e c o g  statements do not recommend 
a single-agent taxane as initial therapy in a patient 
who is anthracycline-naïve and who has metastatic 
breast cancer where h e r 2 is not overexpressed 9,11. 
The n c c n  does not differentiate anthracycline-naïve 
and -pretreated or -resistant patients, but suggests 
that a variety of single-agent taxane regimens can be 
considered 10.
Other Evidence Considered by the Panel:   Two meta-anal-
yses looked at the question of single-agent taxanes as 
compared with single-agent anthracyclines. The meta-
analysis by Piccart–Gebhart et al. pooled individual 
patient data (n = 919) from three randomized trials 12. 
The hazard ratios for the taxane as compared with the 
anthracycline were 1.01 [95% confidence interval (c i): 
0.97 to 1.26] for survival and 1.19 (95% c i : 1.04 to 
1.36) for p f s. Response rates were similar: 38% for 
the single-agent taxane and 33% for the single-agent 
anthracycline. Piccart–Gebhart et al. 12 noted that 
there was significant heterogeneity with respect to 
the finding of improved p f s for the anthracycline as 
compared with the taxane, and that this result was 
largely driven by the European Organisation for the 
Research and Treatment of Cancer (e o r t c) trial 13 
that compared paclitaxel 175 mg/m2 every 3 weeks 
with doxorubicin 75 mg/m2 every 3 weeks. The 
meta-analysis by Ghersi et al. 13 extracted data from 
published trials. The analysis by those authors of the 
same three trials examined by Piccart–Gebhart et al. 12 
found similar results. However, Ghersi et al. 14 looked 
at t t p and did not find a difference between the taxane 
and anthracycline arms.
With respect to toxicities reported in the trials 
included in the meta-analyses, more sensory periph-
eral neuropathy was observed in the taxane arms, 
but more febrile neutropenia, mucositis, nausea 
and vomiting, cardiac failure, and toxic death were 
observed in the anthracycline arms 13,15,16. Quality 
of life was analyzed in all three of the trials, and no 
significant differences were observed between the 
treatment groups with respect to physical, social, 
and emotional functioning, and relationship with 
the treating physician 13,15,16. In one of the trials, 
the toxicities of doxorubicin were offset by better 
symptom control 13.
In the systematic reviews, the taxanes have 
not been compared in subgroup analyses. In the 
e o r t c  trial 13 included in the meta-analyses, o s 
was inferior in the paclitaxel group (15.6 months 
vs. 18.3 months). One phase iii trial randomized 
patients with anthracycline-pretreated metastatic 
breast cancer to receive either docetaxel 100 mg/m2 
or paclitaxel 175 mg/m2 every 3 weeks 17. Overall 
t a b l e  i  External review questionnaire
Question Response frequency
Neutral Agree Strongly 
agree
The guideline panel is credible. 1 4
The guideline is unlikely to be influenced by vested interests. 2 3
Rationale for developing the guideline is clear. 2 3
There is a need for a provincial guideline on this topic. 2 3
The literature search is relevant and complete. 1 4
I agree with the methodology used for summarizing the evidence. 1 4
The results are interpreted according to my understanding of data. 2 3
The draft recommendations are clear. 1 4
The draft recommendations are reasonable. 2 3
When applied, the recommendations will produce more benefit than harm for patients. 1 4
The recommendations are suitable for the intended patients. 2 3
The draft report presents options that will be acceptable to patients. 1 4
When applied, the recommendations would result in better use of resources than current usual 
practice.
1 2 2
Following the recommendations would not require reorganization of services in my practice setting. 2 3
The draft recommendations are likely to be supported by most of my colleagues. 3 2
The draft report should be approved as practice guideline. 3 2KING et al.
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survival and t t p were significantly better for the 
docetaxel arm at the expense of greater hematologic 
and non-hematologic toxicities.
The panel agreed to include weekly taxane regi-
mens as an option. The evidence and rationale are 
largely drawn from the anthracycline-pretreated set-
ting and are further discussed in subsection 5.2.
Summary Statement:   The c c o  recommendation was 
adapted. In support of this recommendation, the panel 
acknowledged the results of the two meta-analyses, 
the individual trial data included in the meta-analyses, 
and one study of docetaxel compared with paclitaxel 
every 3 weeks (from the anthracycline-pretreated set-
ting). Including weekly taxane regimens as an option 
was a de novo addition.
5.1.2  Recommendation 2
If combination chemotherapy is preferred, non-tax-
ane/anthracycline and taxane/anthracycline regimens 
are acceptable alternatives. Taxane/anthracycline 
combinations are superior with respect to overall re-
sponse and p f s, but have not been shown to improve 
o s . Additionally, an o s  benefit for using a taxane/
anthracycline combination over planned sequential 
single-agent anthracycline followed by single-agent 
taxane (before disease progression or at the time of 
disease progression) has not been shown.
With respect to possible taxane/anthracycline 
regimens, doublets of docetaxel or paclitaxel plus 
doxorubicin or epirubicin, and the triplet docetaxel/
doxorubicin/cyclophosphamide have been studied.
Recommendations from Existing Guidelines:   The c c o  
guideline states that docetaxel or paclitaxel in combi-
nation with doxorubicin can be considered 6. This rec-
ommendation contrasts with that in the n i c e  guideline. 
The n i c e  guideline evaluated data only for docetaxel/
anthracycline combinations. It recommends against 
such combination therapy for the reason of unknown 
effectiveness of sequential therapy 7.
The n c c n  statement lists docetaxel or paclitaxel 
in combination with doxorubicin as options 10. The 
b c c a  and c e c o g  statements do not consider taxane/
anthracycline combinations as options for anthracy-
cline-naïve patients 9,11.
Other Evidence Considered by the Panel:   The meta-
analyses by the Piccart–Gebhart and Ghersi groups 
also addressed the issue of taxane/anthracycline 
regimens as compared with non-taxane/anthracycline 
combination therapy 12,14. Piccart–Gebhart et al. in-
cluded individual patient data from eight randomized 
trials. Docetaxel was the taxane in four of those trials, 
and paclitaxel was the taxane in the other four. The 
hazard ratios for the taxane/anthracycline regimen as 
compared with the non-taxane/anthracycline combi-
nation were 0.95 (95% c i : 0.88 to 1.03) for o s  and 
0.92 (95% c i : 0.85 to 0.99) for p f s.
Response rates significantly favoured the taxane/
anthracycline regimens (57% vs. 46%). The authors 
postulated that patients with worse prognosis (visceral or 
estrogen receptor–negative disease) would benefit from 
taxane/anthracycline regimens, but this hypothesis was 
not supported in subgroup analyses. Ghersi et al. 14 identi-
fied nine potentially eligible studies for this question, but 
only three studies had reported time-to-event data. Doc-
etaxel was the taxane in one of the trials, and paclitaxel 
was the taxane in the other two trials. The hazard ratios 
for the taxane/anthracycline regimens as compared with 
the non-taxane combinations were 0.88 (95% c i : 0.76 to 
1.02) for o s  and 0.81 (95% c i : 0.70 to 0.94) for t t p. Five 
trials reported information on response. The odds ratio 
for response for the taxane/anthracycline regimens as 
compared with the non-taxane/anthracycline combina-
tions was 1.7 (95% c i : 1.39 to 2.08).
Four studies provided adequate data on toxicity. 
The taxane/anthracycline regimens were associated 
with significantly more leucopenia and neurotoxicity, 
but less nausea and vomiting. No difference in q o l  
was observed.
Again, the systematic reviews did not compare the 
taxanes in subgroup analyses. One phase iii trial that 
compared docetaxel/doxorubicin with paclitaxel/doxo-
rubicin has been published 18. Outcomes were not sig-
nificantly different in terms of median o s  (22.6 months 
vs. 24.1 months) and response (40% vs. 42%). More 
peripheral neuropathy was observed in the paclitaxel 
group. No difference was observed between the groups 
with respect to q o l , although some subscores favoured 
the docetaxel/doxorubicin group.
The panel was also interested in the issue of tax-
ane/anthracycline combinations as compared with 
sequencing of single-agent anthracycline to single-
agent taxane. Two trials have examined planned 
sequential anthracycline followed by taxane (before 
progression) 19,20. Alba et al. randomized women with 
metastatic breast cancer to docetaxel 75 mg/m2 with 
doxorubicin 50 mg/m2 every 3 weeks for 6 cycles, or 
doxorubicin 75 mg/m2 every 3 weeks for 3 cycles, 
followed by docetaxel 100 mg/m2 every 3 weeks 
for 3 cycles 19. Women who were anthracycline-
pretreated and randomized to the combination arm 
received 3 cycles of docetaxel with doxorubicin, 
followed by 3 cycles of docetaxel 100 mg/m2 every 
3 weeks. No significant differences were observed 
for median o s  (21.8 months vs. 22.3 months), median 
t t p (9.2 months vs. 10.5 months), or overall response 
(51% vs. 61%). Conte et al. randomized participants to 
paclitaxel 200 mg/m2 with epirubicin 90 mg/m2 every 
3 weeks for 8 cycles, or epirubicin 120 mg/m2 every 
3 weeks for 4 cycles followed by paclitaxel 250 mg/
m2 every 3 weeks for 4 cycles 20. No significant dif-
ferences were observed for median o s  (20 months vs. 
26 months), median p f s (10.8 months vs. 11 months), 
or overall response (58.5% vs. 57.6%). Assessment 
of q o l  suggested better functioning and symptom 
control for the combination arm.PRACTICE GUIDELINE SERIES
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Sledge et al. were able to compare the issue of 
taxane/anthracycline combination with sequencing 
of single agents at progression 16. The three arms in 
that trial were paclitaxel 150 mg/m2 with doxoru-
bicin 50 mg/m2 every 3 weeks, paclitaxel 175 mg/
m2 every 3 weeks followed by doxorubicin 60 mg/
m2 every 3 weeks at progression, and doxorubicin 
60 mg/m2 every 3 weeks followed by paclitaxel 
175 mg/m2 every 3 weeks at progression. Just over 
half the participants in the single-agent arms crossed 
over to the alternate single agent at progression. No 
significant differences were found for median o s  
between the combination arm and either sequen-
tial single-agent arm (22 months vs. 22 months 
vs. 18.9 months). Time to failure was significantly 
longer, and response rate was significantly higher 
for the combination arm as compared with either 
sequential single-agent arm.
Summary Statement:   The c c o  recommendation was 
adapted. In support of this recommendation, the panel 
acknowledged the results of two meta-analyses and 
one trial of docetaxel/doxorubicin compared with 
paclitaxel/doxorubicin. Data on taxane/anthracycline 
combinations compared with sequential single agents 
were also considered.
5.2  Anthracycline-Pretreated or -Resistant Patients
5.2.1  Recommendation 1
If single-agent chemotherapy is preferred, a taxane 
regimen is recommended. Single-agent taxanes ap-
pear to improve o s  and response as compared with 
non-taxane/non-anthracycline regimens.
The following regimen is recommended:
Docetaxel 100 mg/m •  2 every 3 weeks
Weekly taxane regimens are also a reasonable 
option if minimization of risk for certain toxicities 
associated with docetaxel every 3 weeks is desired:
Docetaxel 35–40 mg/m •  2 weekly every 4 weeks for 
3 cycles, or weekly every 8 weeks for 6 cycles
Paclitaxel 80–90 mg/m •  2 weekly
Recommendations from Existing Guidelines:   The c c o  
and n i c e  guidelines both suggest that single-agent 
docetaxel and paclitaxel are options 6,7. The c c o 
guideline takes the stance that the evidence for using 
docetaxel every 3 weeks is more consistent and is 
based on larger trials than is the evidence for using 
paclitaxel every 3 weeks 6. The c c o  suggests reserv-
ing weekly taxane regimens (options not specified) 
for patients who are elderly, have a low performance 
status, or would prefer avoiding some of the toxici-
ties associated with taxanes every 3 weeks 6. The n i c e  
guideline is nondirective in terms of the single-agent 
regimens that can be considered.
The panel noted that the recent b c c a , n c c n , and 
c e c o g  statements also suggest that single-agent tax-
anes are options 9–11. The b c c a  considers docetaxel 
every 3 weeks and weekly, plus paclitaxel every 
3 weeks 9. The n c c n  considers both docetaxel and pa-
clitaxel every 3 weeks and weekly, plus nab-paclitaxel 
every 3 weeks 10. The c e c o g  is nondirective in terms of 
the single-agent regimens that can be considered11.
Other Evidence Considered by the Panel:   Compared with 
non-taxane/non-anthracycline regimens, single-agent 
taxanes appear to improve o s  and response. It was 
possible to pool o s  data from four of the five stud-
ies outlined in Table ii. Figure 1 shows that, using a 
random-effects model, the odds ratio for survival was 
0.68 (95% c i : 0.36 to 1.3) with a trend favouring the 
single-agent taxane. Data on overall response rate 
from all five studies in Table ii were pooled. Figure 2 
shows that, using a random-effects model, the rate 
ratio for overall response was 2.23 (95% c i : 1.43 to 
3.49) favouring the single-agent taxane.
Paclitaxel 175 mg/m2 every 3 weeks was not 
included as an option by the panel. First, three of the 
five studies in Table ii were of docetaxel compared 
with a non-taxane/non-anthracycline regimen. The 
three docetaxel studies were much larger than the 
two paclitaxel studies. Second, one randomized 
phase iii trial of docetaxel 100 mg/m2 compared with 
paclitaxel 175 mg/m2, both every 3 weeks, showed 
significantly longer median survival in the docetaxel 
group (15.4 months vs. 12.7 months) and significantly 
longer median t t p (5.7 months vs. 3.6 months) 17. 
However, the docetaxel benefit came at the cost of more 
hematologic and non-hematologic toxicity: febrile 
neutropenia (14.9% vs. 1.8%), stomatitis/mucositis 
(10.8% vs. 0%), nausea and vomiting (8.6% vs. 2.7%), 
and sensory peripheral neuropathy (7.2% vs. 4.1%). 
Quality-of-life scores were not significantly different.
Evidence for the effectiveness—and perhaps 
more favourable toxicity profiles—associated with 
weekly taxane regimens is mounting.
f i g u r e  1 Single-agent taxane compared with non-taxane/
non-anthracycline: meta-analysis of overall survival 21–24. 
C i  = confidence interval.KING et al.
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Weekly Docetaxel:   One phase iii trial compared 
docetaxel 35–40 mg/m2 weekly every 4 weeks 
for 3 cycles with docetaxel 75–100 mg/m2 every 
3 weeks 26. No significant difference was ob-
served with respect to median o s  (18.6 months 
vs. 18.3 months) or median p f s (5.5 months vs. 
5.7 months). However, in the weekly group, overall 
response was lower (20.3% vs. 35.6%). Also in the 
weekly group, febrile neutropenia (3% vs. 10%), 
myalgias (3% vs. 27%), and fatigue (13.5% vs. 25%) 
were less frequently observed.
A randomized phase ii trial 27 of docetaxel 40 mg/
m2 weekly every 8 weeks for 6 cycles compared with 
docetaxel 100 mg/m2 every 3 weeks showed a longer 
median o s  for the weekly group (29.1 months vs. 
20.1 months), but similar median t t p (5.7 months vs. 
5.3 months) and overall response (34.1% vs. 33.3%). 
However, the weekly group appeared to experience 
less febrile neutropenia (4.9% vs. 19.5%), nausea and 
vomiting (12.2% vs. 14.6%), stomatitis and mucositis 
(7.3% vs. 17.1%), and sensory peripheral neuropathy 
(2.4% vs. 17.1%). In that study, slightly more asthenia 
and fatigue (14.6% vs. 12.2%) and more anorexia (4.9% 
vs. 0%) appeared to be associated with the weekly as 
compared with the every-three-weeks regimen.
Where reported, phase ii studies of weekly doc-
etaxel suggest a quite variable incidence of asthenia 
and fatigue, ranging from 7% to 47% as summarized 
in the c c o  guideline 6.
Weekly Paclitaxel:   Two randomized trials have 
compared weekly with every-three-weeks pacli-
taxel. Seidman et al. compared paclitaxel 80 mg/m2 
weekly with paclitaxel 175 mg/m2 every 3 weeks 28. 
Notably, participants with h e r 2-negative disease 
were also randomized to receive or not receive 
trastuzumab, and all participants with h e r 2-positive 
disease received trastuzumab. Across the entire 
study population, the weekly group showed a trend 
to longer median o s  (24 months vs. 12 months), but 
this result was not statistically significant. Time 
to progression for the weekly regimen was signifi-
cantly longer (9 months vs. 5 months), and overall 
response was significantly higher (42% vs. 29%). 
The incidences of febrile neutropenia (3% vs. 4%), 
nausea and vomiting (<5%, both arms), and stoma-
titis and mucositis (<5%, both arms) were similar 
for the treatment groups. Rates for these important 
toxicities are acceptably low. The incidence of 
grade 3 sensory peripheral neuropathy was, how-
ever, higher in the weekly group (24% vs. 12%). In 
cases in which h e r 2 was not overexpressed, global 
q o l  and cancer symptom control were significantly 
better in the weekly group 29.
t a b l e  ii  Single-agent taxane compared with non-taxane/non-anthracycline regimens
Reference Phase Treatment arms Pts
(n)
Median p f s
(months)
Median t t p
(months)
Median O s
(months)
O r r
(%)
Bonneterre et al., 1997 21 iii Docetaxel
Vinorelbine/5-f u
86
90
n r
n r
6.5
5.1
16
15
43
38.8
Nabholtz et al., 1999 22 iii Docetaxel
Mitomycin/vinblastine
203
189
16a
10
19a
11
11.4a
8.7
30a
11.6
Sjöström et al., 1999 23 iii Docetaxel
Methotrexate/5-f u
143
139
n r
n r
6.3a
3.0
10.4
11
42a
21
Dieras et al., 1995 24 ii Paclitaxel
Mitomycin
36
36
9.1
6.7
3.5b
1.6
12.7
8.4
15
5
Talbot et al., 2002 25 ii Paclitaxel
Capecitabine
19
22
n r
n r
3.1
3.0
9.4
7.6
36
26
a   p < 0.01.
b  p < 0.05.
Pts = patients; p f s = progression-free survival; t t p = time to progression; o s  = overall survival; o r r  = overall response rate; n r  = (not reported); 
5-f u = 5-fluorouracil.
f i g u r e  2 Single-agent taxane compared with non-taxane/
non-anthracycline: meta-analysis of overall response 21–25. 
C i  = confidence interval.PRACTICE GUIDELINE SERIES
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Verrill et al. compared paclitaxel 90 mg/m2 weekly 
for 12 cycles with paclitaxel 175 mg/m2 every 3 weeks 
for 6 cycles 30. No difference was detected with re-
spect to o s . The weekly group showed a trend toward 
longer median t t p (6 months vs. 5.5 months) and a 
significantly higher response rate (43% vs. 27%). 
Toxicity profiles of the two arms were similar.
Data from the neoadjuvant and adjuvant settings 
also suggest that weekly paclitaxel may be more effec-
tive than an every-three-weeks regimen. In the neoadju-
vant setting, Green et al. examined weekly as compared 
with every-three-weeks paclitaxel regimens 31. Results 
for the primary outcome (clinical complete response) 
were not statistically different. For the weekly regimen, 
pathologic complete response was significantly better 
(28.2% vs. 15.7%), as was the breast conservation rate 
(47% vs. 38%). Again, neurotoxicity was worse with 
the weekly regimen.
In women with resected high-risk node-negative 
or node-positive breast cancer, Eastern Cooperative 
Oncology Group study 1199 explored various taxane 
schedules (weekly vs. every-three-weeks paclitaxel and 
docetaxel) following a backbone of doxorubicin and 
cyclophosphamide 32. The standard therapy was every-
three-weeks paclitaxel. The hazard ratio for disease-free 
survival in patients receiving weekly paclitaxel was 
1.27 (p = 0.006); weekly docetaxel, 1.23 (p = 0.02); and 
every-three-weeks docetaxel, 1.09 (p = 0.29). Weekly 
paclitaxel was also associated with improved survival 
(hazard ratio: 1.32; p = 0.01). In an exploratory analysis 
of patients with estrogen receptor–negative disease, 
the weekly paclitaxel and every-three-weeks docetaxel 
arms both proved to be superior to every-three-weeks 
paclitaxel in terms of disease-free survival (81.5% and 
81.2% respectively vs. 76.9%). The weekly paclitaxel 
regimen was superior to every-three-weeks paclitaxel in 
terms of o s  (89.7% vs. 86.5%). The docetaxel groups had 
higher incidences of febrile neutropenia, and the weekly 
paclitaxel group had a significantly higher incidence of 
neuropathy.
Summary Statement:   The c c o  and n i c e recommenda-
tions for use of single-agent taxanes were adapted. 
More current evidence in support of recommending 
docetaxel over paclitaxel every 3 weeks, and further 
evidence in support of weekly taxane regimens, 
was available.
5.2.2  Recommendation 2
If combination chemotherapy is preferred, taxane/
non-anthracycline regimens are recommended. 
Compared with single-agent taxanes, taxane/non-
anthracycline regimens are superior with respect to 
o s  and response. Definitive survival data for taxane/
non-anthracycline combinations in comparison with 
sequential single-agent taxane followed by single-
agent non-taxane/non-anthracycline (at progression) 
are not available.
The following taxane/non-anthracycline regimens 
should be options:
Docetaxel 75 mg/m •  2 day 1, with capecitabine 
1250 mg/m2 twice daily on days 1–14, every 
3 weeks
Docetaxel 75 mg/m •  2 day 1, with gemcitabine 
1000 mg/m2 on days 1 and 8, every 3 weeks
Paclitaxel 175 mg/m •  2 day 1, with gemcitabine 
1250 mg/m2 days 1 and 8, every 3 weeks
Recommendations from Existing Guidelines:   The c c o  
guideline includes docetaxel with capecitabine as an 
option in younger patients with good performance 
status 6. Assessment of the other regimens (by the c c o  
guideline examined) and of all taxane/non-anthracy-
cline regimens (by n i c e ) was not possible because of 
lack of data at the time. However, the c c o  has recently 
updated a guideline specifically on the role of gem-
citabine in the management of metastatic breast can-
cer 33. In that guideline, the authors conclude, based 
on a trial that our panel also examined, that docetaxel 
with gemcitabine can be considered an alternative 
to docetaxel with capecitabine. The c c o  guideline 
also concludes that paclitaxel with gemcitabine is an 
option, but that the clinical relevance questionable, 
given that docetaxel has been the preferred taxane for 
use in metastatic breast cancer in Ontario.
The panel noted that the b c c a , n c c n , and c e c o g  
statements also include taxane/non-anthracycline 
regimens as options 9–11. The b c c a  considers docetaxel 
with capecitabine, or paclitaxel with gemcitabine, in 
the setting of an aggressive relapse in a fit patient 9. 
The n c c n  considers the same two options 10. The 
c e c o g  states that a taxane in combination with either 
capecitabine or gemcitabine can be considered 11.
Other Evidence Considered by the Panel:   In a large 
phase iii trial of docetaxel with capecitabine com-
pared with docetaxel alone, the combination regimen 
was found to be superior with respect to several 
endpoints: median o s  (14.5 months vs. 11.5 months), 
median t t p (6.1 months vs. 4.2 months), and overall 
response rate (42% vs. 30%) 34. The incidence of 
febrile neutropenia was similar (13% vs. 16%). As 
expected, the combination regimen was associated 
with a higher incidence of capecitabine-related tox-
icities. No differences between the arms were found 
with respect to q o l .
In a large phase iii trial of paclitaxel with gem-
citabine compared with paclitaxel alone, the combi-
nation regimen was found to be superior in terms of 
median o s  (18.5 months vs. 15.8 months) and median 
t t p (5.2 months vs. 2.9 months) 35. With the combina-
tion regimen, the overall response rate appeared to be 
superior (40.8% vs. 22.1%), but this finding was not 
statistically significant. Clinically relevant reported 
toxicities appeared to be similar between the two 
groups: febrile neutropenia (5% vs. 1%), nausea and KING et al.
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vomiting (2% vs. 2%), and sensory peripheral neu-
ropathy (5% vs. 4%). Global q o l  was significantly 
better in the combination arm.
One phase iii study compared docetaxel/gemcit-
abine with docetaxel/capecitabine 36. Data on o s  have 
not been presented, but no differences were observed 
with respect to median p f s (35 weeks vs. 35 weeks) or 
overall response rate (32% vs. 32%). A trend toward 
less febrile neutropenia was observed in the doc-
etaxel/gemcitabine arm (8% vs. 13%). As expected, 
mucositis, diarrhea, and hand–foot syndrome were 
observed significantly less frequently in the docetaxel/
gemcitabine arm.
One randomized phase ii study suggested 
similar outcomes for docetaxel/gemcitabine, every-
three-weeks paclitaxel/gemcitabine, and weekly 
paclitaxel (days 1 and 8)/gemcitabine: median t t p 
(7.4 months vs. 7.5 months vs. 7.0 months) and 
overall response rate (50.3% vs. 48.6% vs. 52.3%) 37. 
Data on o s  have not yet been reported. The incidence 
of febrile neutropenia appeared to be highest in 
the docetaxel/gemcitabine group (11.8% vs. 0% vs. 
4.4%). Hence, docetaxel/gemcitabine cannot yet 
be recommended over docetaxel/capecitabine or 
paclitaxel/gemcitabine with respect to effectiveness. 
Docetaxel/gemcitabine could be offered in place of 
docetaxel/capecitabine if there is a preference to 
avoid capecitabine-related toxicities. Weekly pacli-
taxel with gemcitabine cannot yet be recommended 
over every-three-weeks paclitaxel with gemcitabine. 
Docetaxel/capecitabine have not been directly com-
pared with paclitaxel/gemcitabine.
In the docetaxel/capecitabine 34 versus docetaxel 
and the paclitaxel/gemcitabine versus paclitaxel 35 
studies, crossover from the single-agent taxane to 
the single-agent non-taxane/non-anthracycline at 
the time of progression was not planned. One ran-
domized phase ii trial compared docetaxel 75 mg/
m2 with capecitabine 1250 mg/m2 twice daily on 
days 1–14 every 3 weeks with docetaxel 100 mg/m2 
every 3 weeks followed by capecitabine 1250 mg/m2 
twice daily on days 1–14 every 3 weeks at the time of 
disease progression 35. Median t t p was longer in the 
combination group (9.3 months vs. 7.7 months), and 
the overall response rate was higher (68% vs. 40%). 
No difference for median o s  was found (22 months 
vs. 19 months).
Data on overall response rate from the docetaxel/
capecitabine versus docetaxel 34, paclitaxel/gemcit-
abine versus paclitaxel 35, and docetaxel/capecitabine 
versus sequential docetaxel to capecitabine 38 studies, 
as summarized in Table iii, were pooled. Figure 3 
shows that, using a random effects model, the rate 
ratio for overall response was 1.69 (95% c i : 1.26 to 
2.11) favouring taxane/non-anthracycline combina-
tions. Given the heterogeneous trial designs—that 
is, whether planned crossover occurred or did not 
occur in the single-agent arms—survival data were 
not pooled.
Summary Statement:   The c c o  recommendation for 
docetaxel/capecitabine was adapted. More recent 
evidence for docetaxel/gemcitabine and paclitaxel/
gemcitabine was considered by the panel so as to 
create an updated recommendation on the role of 
taxane/non-anthracycline regimens.
5.3  Anthracycline-Naïve, -Pretreated, or -Resistant 
Patients with Corticosteroid Intolerance
5.3.1  Recommendation 1
In the setting of corticosteroid intolerance, the fol-
lowing single-agent nanoparticle albumin-bound 
paclitaxel (nab-paclitaxel) regimens should be op-
tions where docetaxel or paclitaxel would otherwise 
be prescribed:
Nab-paclitaxel 260–300 mg/m •  2 every 3 weeks
Nab-paclitaxel 100–150 mg/m •  2 weekly every 
4 weeks for 3 cycles
Recommendations from Existing Guidelines:   The c c o  
and n i c e guidelines examined were unable to make 
recommendations regarding nab-paclitaxel because 
of the lack of available data at the time. However, 
the c c o  recently published a report specifically 
on the role of nab-paclitaxel in the treatment of 
metastatic breast cancer 39. The authors concluded 
that women with metastatic breast cancer who are 
eligible for single-agent paclitaxel could be offered 
nab-paclitaxel as an alternative. No recommendation 
for specific regimens was made. The b c c a  and c e c o g  
did not address the role of nab-paclitaxel. The panel 
noted that the n c c n  considers nab-paclitaxel every 
3 weeks to be an option 10.
Other Evidence Considered by the Panel:   The panel 
concluded that nab-paclitaxel should be available 
only in the setting of corticosteroid intolerance in 
situations in which docetaxel or paclitaxel would 
otherwise be prescribed. First, without corticoster-
oid or antihistamine pre-medication, nab-paclitaxel 
is associated with hypersensitivity reactions (inci-
dence: <1%) 40. Second, despite the low incidence of 
f i g u r e  3 Taxane/non-anthracycline regimen compared 
with single-agent taxane: meta-analysis of overall re-
sponse 34,35,38. C i  = confidence interval.PRACTICE GUIDELINE SERIES
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hypersensitivity reactions without pre-medication, 
the safety of nab-paclitaxel after a demonstrated hy-
persensitivity reaction to docetaxel or paclitaxel has 
not been proved, and hence, nab-paclitaxel cannot 
currently be recommended in that setting. Finally, in 
the absence of definitive data showing improved o s  
or significantly reduced toxicities for nab-paclitaxel 
as compared with any of the solvent-based taxane 
regimens, the panel felt that nab-paclitaxel should 
not be routinely offered as a single-agent option.
One randomized phase ii study compared three 
nab-paclitaxel arms (300 mg/m2 every 3 weeks, 
100 mg/m2 weekly for 3 of 4 weeks for 3 cycles, and 
150 mg/m2 weekly for 3 of 4 weeks for 3 cycles) and 
one docetaxel arm (100 mg/m2 every 3 weeks) 41. All 
three nab-paclitaxel arms showed reduced hazard for 
disease progression as compared with the every-three-
weeks docetaxel arm. The p f s curve for nab-paclitaxel 
150 mg/m2 weekly appeared to be the most favourable. 
In the weekly study arms, response was significantly 
higher than it was in either the every-three-weeks nab-
paclitaxel arm or the docetaxel arm. The incidence of 
febrile neutropenia was 1% in all three nab-paclitaxel 
arms, and 7% in the docetaxel arm. The incidence of 
sensory peripheral neuropathy was lowest in the nab-
paclitaxel 100 mg/m2 weekly arm and the docetaxel 
arm (7% and 5% respectively). In the nab-paclitaxel 
150 mg/m2 weekly arm and the every-three-weeks 
nab-paclitaxel arm, the incidences of sensory periph-
eral neuropathy were 12% and 14%.
In a phase iii trial of nab-paclitaxel 260 mg/m2 
compared with paclitaxel 175 mg/m2, the nab-pacli-
taxel group showed a significantly longer median t t p  
(23 months vs. 16.9 months) and a trend toward longer 
median o s  (65 weeks vs. 55.7 weeks) 40. The incidence 
of sensory peripheral neuropathy in the nab-paclitaxel 
group was 10%, and in the paclitaxel group, it was 2%.
Summary Statement:   The panel largely considered the 
relevant trials of nab-paclitaxel compared with the 
other taxanes to create a de novo recommendation.
5.4  Anthracycline-Naïve, -Pretreated, or -Resistant 
Patients in Whom HER2 Is Overexpressed
5.4.1  Recommendation 1
Up front, a taxane/trastuzumab combination is 
recommended. The addition of trastuzumab to a 
taxane has been shown to improve o s  and response. 
Although the addition of trastuzumab to anthra-
cycline regimens has also been shown to improve 
o s  and response, the incidence of cardiac failure is 
unacceptable. The addition of carboplatin to taxane/
trastuzumab combinations has not yet been shown to 
improve o s  or to consistently increase response.
The strongest evidence is for the following single-
agent taxane regimens, plus trastuzumab:
Docetaxel 100 mg/m •  2 every 3 weeks
Paclitaxel 175 mg/m •  2 every 3 weeks
Recommendations from Existing Guidelines:   The c c o  
and n i c e  guidelines examined did not make specific 
recommendations for patients with metastatic breast 
cancer in which h e r 2 is overexpressed.
The c c o  published a separate guideline on the 
role of trastuzumab in the treatment of women with 
h e r 2-overexpressing metastatic breast cancer 42. 
Either docetaxel or paclitaxel every 3 weeks, plus 
trastuzumab, is recommended as first-line therapy.
The panel noted that, in this setting, the b c c a 
and n c c n  statements recommended the addition of 
trastuzumab to either single-agent docetaxel or pa-
clitaxel, or to paclitaxel/carboplatin 9,10. The c e c o g  
statement recommended the addition of trastuzumab 
to a non-anthracycline regimen, which could include 
a taxane 11.
Other Evidence Considered by the Panel:   A randomized 
phase ii study compared docetaxel alone with docetaxel 
100 mg/m2 every 3 weeks plus weekly trastuzumab 43. 
More than half the participants had been exposed to 
an anthracycline in the adjuvant setting. The addition 
t a b l e  iii  Taxane/non-anthracycline regimen compared with single-agent taxane
Reference Phase Treatment arms Pts 
(n)
Median p f s 
(months)
Median t t p 
(months)
Median O s  
(months)
O r r  
(%)
O’Shaughnessy et al., 2002 34 iii Docetaxel/capecitabine 
Docetaxel
255 
256
n r  
n r
6.1a 
4.2
14.5b 
11.5
42a 
30
Albain et al., 2004 35 
(abstract)
iii Paclitaxel/gemcitabine 
Paclitaxel
267 
262
n r  
n r
5.2b 
2.9
18.5b 
15.8
40.8 
22.1
Beslija et al., 2006 38 
(abstract)
ii Docetaxel/capecitabine 
Docetaxel 
to capecitabine 
at progression
50 
50
n r  
n r
9.3b 
7.7
22 
19
68a 
40
a   p < 0.01.
b  p < 0.05.
Pts = patients; p f s = progression-free survival; t t p = time to progression; o s  = overall survival; o r r  = overall response rate; n r  = not reported; 
5-f u = 5-fluorouracil.KING et al.
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 3
18
of trastuzumab improved median t t p (11.7 months vs. 
6.1 months), median o s  (31.2 months vs. 22.7 months), 
and overall response rate (61% vs. 34%).
A large phase iii study compared paclitaxel alone 
with paclitaxel 175 mg/m2 every 3 weeks plus weekly 
trastuzumab in the anthracycline pre-treated setting, 
and doxorubicin/cyclophosphamide alone with doxo-
rubicin/cyclophosphamide every 3 weeks plus weekly 
trastuzumab in the anthracycline-naïve setting 44. 
The addition of trastuzumab to paclitaxel improved 
median t t p (6.9 months vs. 3.0 months), median o s  
(22.1 months vs. 18.4 months), and overall response 
rate (49% vs. 17%). The addition of trastuzumab to 
doxorubicin/cyclophosphamide also improved me-
dian o s  (26.8 months vs. 21.4 months), but the cardiac 
event rate was unacceptably high (28% vs. 9.6%).
Finally, a randomized phase ii study examined 
weekly paclitaxel 80 mg/m2 plus or minus weekly 
trastuzumab 45. Women with advanced breast cancer 
and 2+ or 3+ overexpression of h e r 2 by immunohis-
tochemistry (i h c ) were included. For the subgroup 
with i h c  3+ (84 of 124), median t t p was significantly 
longer (369 days vs. 272 days), and response was 
significantly higher (75% vs. 56.9%) for those who 
received paclitaxel plus trastuzumab.
The addition of carboplatin to taxane/trastuzumab 
doublets has not yet been shown to improve o s  or 
to consistently improve overall response rates. One 
phase iii trial compared docetaxel/trastuzumab/carbo-
platin with docetaxel/trastuzumab 46. Median t t p was 
similar in the two arms (10.4 months vs. 11.1 months), 
as was overall response rate (73% vs. 73%). Median 
o s  was 41.7 months for the triplet arm, but had not 
yet been reached in the doublet arm.
One phase iii trial compared paclitaxel/trastu-
zumab/carboplatin with paclitaxel/trastuzumab 47. 
Median p f s was longer in the triplet arm (10.7 months 
vs. 7.1 months), and the overall response rate was 
higher (52% vs. 36%). No difference was found 
for median o s  (35.7 months vs. 32.2 months). Both 
regimens were well tolerated, although a higher rate 
of grade 4 febrile neutropenia was observed in the 
carboplatin/paclitaxel/trastuzumab arm.
A protocol for a Cochrane Collaboration system-
atic review examining the efficacy of trastuzumab 
plus other drug therapy, or trastuzumab alone in h e r 2-
positive metastatic breast cancer is still pending.
Summary Statement:   The panel largely considered the 
relevant trials of taxane regimens plus or minus tras-
tuzumab in metastatic breast cancer in which h e r 2 is 
overexpressed to create a de novo recommendation.
5.  CONCLUSIONS
The benefits of taxane chemotherapy in metastatic 
breast cancer have been well established. The goal of 
the present initiative was to provide evidence-based 
guidelines for the use of taxanes in patients with 
metastatic breast cancer. These guidelines have been 
developed through systematic adaptation of existing 
guidelines and the creation of de novo guidelines. 
The 6 recommendations that were formulated will 
be updated annually as new evidence becomes avail-
able. The panel acknowledges that many patients will 
have received taxanes in the adjuvant setting, and the 
decision regarding whether the patient’s disease is 
refractory to taxane treatment is left to the discretion 
of the physician providing treatment.
5.1  Limitations
The major limitation encountered in using the a d a p t e  
process was that the two evidence-based guidelines 
selected, from n i c e  7 and c c o  6, were released in 2001 
and 2003 respectively. A significant amount of evi-
dence that was more current was reviewed to ensure 
up-to-date recommendations. In some instances, de 
novo recommendation development was required.
5.2  Implications for the Alberta Cancer Board
Most regimens recommended or listed as options in 
the present guideline were available through the Al-
berta Cancer Board Outpatient Drug Benefit Program 
(o d b p) as of July 2007 when the draft report was be-
ing sent for external review. Docetaxel/gemcitabine 
would require a formulary addition request to the 
provincial Pharmacy and Therapeutics Committee 
(which takes into account cost implications). Nab-
paclitaxel has been added to the o d b p. In contrast to 
the present guideline, o d b p  criteria for use of nab-
paclitaxel includes “patients who have had severe 
acute infusion reactions with paclitaxel or docetaxel 
considered by the treating physician to be due to the 
vehicle of the taxanes” or “patients who have expe-
rienced severe toxicity from previous administration 
of other taxanes.”
5.3  Implementation
The final draft of the present guideline has been posted 
on the Alberta Cancer Board Web site and distributed 
to all target users.
5.4  Scheduled Review and Update
The Alberta Cancer Board Provincial Breast Tumour 
Group Guideline Panel will meet annually to review 
new guidelines and other pertinent evidence. The 
present guideline will be updated accordingly, and 
target users will be notified.
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